AG003R7D

134678-17-4 | 4-Amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone

AG003R7D

SDS

COA

Price

$0.00

Add to Cart

Buy Now

WARNING This product is not for human or veterinary use.

CAS Number	134678-17-4
Catalog Number	AG003R7D(AGN-PC-0PKDCW)
Chemical Name	4-Amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone
IUPAC Name	4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one
InChI	InChI=1S/C8H11N3O3S/c9-5-1-2-11(8(13)10-5)6-4-15-7(3-12)14-6/h1-2,6-7,12H,3-4H2,(H2,9,10,13)/t6-,7+/m0/s1
InChI Key	JTEGQNOMFQHVDC-NKWVEPMBSA-N
MDL Number	MFCD00869739
Molecular Formula	C8H11N3O3S
Molecular Weight	229.2562
SMILES	O=c1n([C@H]2O[C@H](SC2)CO)ccc(n1)N
UNII	2T8Q726O95
Synonyms	2',3' Dideoxy 3' thiacytidine, 2',3'-Dideoxy-3'-thiacytidine, 3TC, BCH 189, BCH-189, BCH189, Epivir, GR-109714X, GR109714X, Lamivudine, Lamivudine, (2S-cis)-Isomer, lamivudine, 134678-17-4, Epivir, Zeffix, Heptovir, Epivir-HBV, Hepitec, Heptodin, BCH-189, 3TC, Heptivir, (-)-2'-Deoxy-3'-thiacytidine, CIS-LAMIVUDINE, GR109714X, GR-109714X, 3'-Thia-2',3'-dideoxycytidine, 4-amino-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)pyrimidin-2(1H)-one, (-)-BCH-189, Lamivudine [USAN:BAN:INN], beta-L-2',3'-Dideoxy-3'-thiacytidine, beta-L-3'-Thia-2',3'-dideoxycytidine, (-)NGPB-21, 2',3'-Dideoxy-3'-thiacytidine, (-)-BCH 189, UNII-2T8Q726O95, HSDB 7155, GR 109714X, 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1H)-one, 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one, BCH 189, (-)-, C8H11N3O3S, CHEBI:63577, (-)-1-((2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine, (-)-1-[(2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine, 4-Amino-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone, MFCD00869739, 2T8Q726O95, CPD000466319, Lamivir, Zefix, 136891-12-8, 2(1H)-Pyrimidinone, 4-amino-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-, (2R-cis)-, BCH 189, (-)-(2'R,5'S)-1-[2'-Hydroxymethyl-5'-(1,3-oxathiolanyl)]cytosine, 2(1H)-Pyrimidinone, 4-amino-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-, 4-AMINO-1-[(2R,5S)-2-(HYDROXYMETHYL)-1,3-OXATHIOLAN-5-YL]-2(1H)-PYRIMIDINONE, Epivir(TM), HHA & Lamivudine, Lamivudine & GNA, SMR000466319, Lamivudine [USAN:INN:BAN], Epivir (TN), DTHC, CHEMBL141, DRG-0126, 3TC and NV-01, (-)-SddC, Lamivudina, Lamivudinum, Lamivudin, Lamivudine (JAN/USP/INN), 3TC & GNA, 3TC & SST, HHA & 3TC, (+/-)-SddC, CCRIS 9274, NSC620753, 2(1H)-Pyrimidinone, 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-, BCH-790, Lamivudine [USAN:USP:INN:BAN], Lamivudine(Epivir), NCGC00159341-04, Lamivudine, 98%, GG-714, Lamivudine (EPIVIR), (+/-)-3TC, (+/-)-BCH-189, AC1L1TZZ, 3TC (AIDS INITIATIVE) (AIDS INITIATIVE), MLS000759424, MLS001424097, MLS006011910, BIDD:GT0033, SCHEMBL109675, AC1Q6C34, PYR356, CTK3J2124, ZINC12346, JTEGQNOMFQHVDC-NKWVEPMBSA-N, HMS2051D21, HMS3259F08, HMS3713C16, HY-B0250, ANW-43098, BBL033871, BDBM50366817, s1706, SBB066293, STK801940, lamivudine & TNF-alpha & IFN-gamma, AKOS005622556, AKOS015854841, Lamivudine, >=98% (HPLC), powder, AB07588, AC-1416, AN-7245, CCG-100984, CS-2230, DB00709, KS-1073, LS-2107, MCULE-2096184994, NC00234, NC00705, RL01569, RTC-020973, (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one, KS-0000023D, NCGC00159341-05, 4-AMINO-1-[(2R,5S)-2-(HYDROXYMETHYL)-1,3-OXATHIOLAN-5-YL]-1,2-DIHYDROPYRIMIDIN-2-ONE, AJ-08348, BC206089, CJ-00130, LMV, SAM001246582, SAM002589994, SC-15184, ZB000700, FT-0082667, FT-0601626, FT-0650554, L0217, ST24030826, SW197614-3, C07065, D00353, J10244, M-9795, 24222-EP2269989A1, 24222-EP2272516A2, 24222-EP2272825A2, 24222-EP2292227A2, 24222-EP2298761A1, 24222-EP2298783A1, 24222-EP2305243A1, 24222-EP2305640A2, 24222-EP2305680A2, 24222-EP2314590A1, AB00639995-06, AB00639995-08, AB00639995_09, 200973-EP2272825A2, 678L174, SR-01000759420, J-700183, Q-201275, SR-01000759420-5, Lamivudine, British Pharmacopoeia (BP) Reference Standard, Lamivudine, European Pharmacopoeia (EP) Reference Standard, (2R,5S)-1-[2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine, .beta.-L-(-)-2',3'-dideoxy-3'-thiacytidine & Sho-Saiko-To, Lamivudine, United States Pharmacopeia (USP) Reference Standard, (+/-) (Cis)-1-[2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine, (-)-L-2',3'-DIDEOXY-3'-THIACYTIDINE; LAMIVUDINE; EPIVIR, Lamivudine, 1.0 mg/mL in methanol, certified reference material, Lamivudine, Pharmaceutical Secondary Standard; Certified Reference Material, (+/-)-(cis)-4-Amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one, 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (+/-) (Cis), 3-[(5S,2R)-2-(hydroxymethyl)(1,3-oxathiolan-5-yl)]-6-amino-3-hydropyrimidin-2- one, 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-[1,3]-oxathiolan-5-yl]-(1H)-pyrimidin-2-one, 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-Oxathiolan-5-yl]-(1H)-pyrimidin-2-one, cis(+/-)-4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone, Lamivudine for system suitability 1, European Pharmacopoeia (EP) Reference Standard, Lamivudine for system suitability 2, European Pharmacopoeia (EP) Reference Standard, 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)(2R,5S) & Galanthus Nivalis Agglutinin (GNA), 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)(2R,5S) & Hippeastrum hybrid agglutinin( HHA), Combivir, Trizivir, Epzicom, Kuvan, Lamivudine ViiV, Mixture Name, Epivir HBV, VIROLAM, Heptovir (TN), Zeffix (TN), Epivir-HBV (TN), L-SDDC, D07TQV, D0V7DY, 2'-deoxy-3'-thiacytidine, Lamivudine, (2S-cis)-Isomer, BCH189, 2',3' Dideoxy 3' thiacytidine, (-)-NGPB-21, CID60825, C8-H11-N3-O3-S, CL0014, Efavirenz/lamivudine/tenofovir fumarate, ACN-029244, CS-O-10971, (-)-beta-L-2',3'-Dideoxy-3'-thiacytidine, BCH 189 (-)-, 1 3-Oxathiolane 2(1H)-pyrimidinone deriv., D019259, 2-Hydroxymethyl-5-(cytosin-1-yl)-1 3-oxathiolane, 3TC, Zeffix, Heptovir, Epivir, Epivir-HBV, Lamivudine, cis(-)-2-Hydroxymethyl-5-(cytosin-1-yl)-1 3-oxathiolane, Beta-L-(-)-2',3'-dideoxy-3'-thiacytidine & Sho-Saiko-To, (+/-)-(Cis)-1-[2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine, (-)-1-((2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl)cystosine, 4-Amino-1-(cis-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)pyrimidin-2(1H)-one, 2(1h)-pirimidinona, 4-amino-1-[(2r,5s)-2-(hidroximetil)-1,3-oxatiolan-5-il]-, 2(1H)-Pyrimidinone 4-amino-1-[2-(hydroxymethyl)-1 3-oxathiolan-5-yl]-(2R-cis)-, 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (+/-)-(Cis), 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)(2R,5S), 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)-(2R,5S), Lamivudine, 98%, a potent nucleoside analog reverse transcriptase inhibitor - 100MG 100mg, 134680-32-3, 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)-(2R,5S) & Galanthus Nivalis Agglutinin (GNA), 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)-(2R,5S) & Hippeastrum hybrid agglutinin(HHA),

Complexity	331
Compound Is Canonicalized	Yes
Covalently-Bonded Unit Count	1
Defined Atom Stereocenter Count	2
Defined Bond Stereocenter Count	0
Exact Mass	229.052g/mol
Formal Charge	0
Heavy Atom Count	15
Hydrogen Bond Acceptor Count	4
Hydrogen Bond Donor Count	2
Isotope Atom Count	0
Molecular Weight	229.254g/mol
Monoisotopic Mass	229.052g/mol
Rotatable Bond Count	2
Topological Polar Surface Area	113A^2
Undefined Atom Stereocenter Count	0
Undefined Bond Stereocenter Count	0
XLogP3	-0.9

GHS Hazard and Precautionary Statements

Symbol:
Hazard Class
Hazard statements	H302
Packing Group
Precautionary statements	P280-P305+P351+P338
UN Code	\N

Certificate of Analysis

Lot Number